ATE534038T1 - Neurodegenerative marker für alzheimer-krankheit - Google Patents

Neurodegenerative marker für alzheimer-krankheit

Info

Publication number
ATE534038T1
ATE534038T1 AT09013088T AT09013088T ATE534038T1 AT E534038 T1 ATE534038 T1 AT E534038T1 AT 09013088 T AT09013088 T AT 09013088T AT 09013088 T AT09013088 T AT 09013088T AT E534038 T1 ATE534038 T1 AT E534038T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
markers
neurodegenerative
values
Prior art date
Application number
AT09013088T
Other languages
English (en)
Inventor
Aye Mu Myint
Manfred Schawaller
Markus J Schwarz
Harald Hampel
Original Assignee
Univ Antwerp
Univ Maastricht
Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie
Verstappen Leopold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Antwerp, Univ Maastricht, Klinik Und Poliklinik Fuer Psychiatrie Und Psychotherapie, Verstappen Leopold filed Critical Univ Antwerp
Application granted granted Critical
Publication of ATE534038T1 publication Critical patent/ATE534038T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Mushroom Cultivation (AREA)
  • Input From Keyboards Or The Like (AREA)
AT09013088T 2005-04-06 2006-03-30 Neurodegenerative marker für alzheimer-krankheit ATE534038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007558 2005-04-06

Publications (1)

Publication Number Publication Date
ATE534038T1 true ATE534038T1 (de) 2011-12-15

Family

ID=36293430

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09013088T ATE534038T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für alzheimer-krankheit
AT06723873T ATE468537T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für depression.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06723873T ATE468537T1 (de) 2005-04-06 2006-03-30 Neurodegenerative marker für depression.

Country Status (13)

Country Link
US (2) US20080131921A1 (de)
EP (2) EP2146209B1 (de)
JP (1) JP4958893B2 (de)
AT (2) ATE534038T1 (de)
CY (1) CY1110116T1 (de)
DE (1) DE602006014379D1 (de)
DK (2) DK1866650T3 (de)
ES (2) ES2346467T3 (de)
NO (2) NO20075671L (de)
PL (2) PL1866650T3 (de)
PT (2) PT1866650E (de)
SI (1) SI1866650T1 (de)
WO (1) WO2006105907A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016101A1 (en) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Method for evaluation of stress, stress evaluation apparatus, stress evaluation method, stress evaluation system, stress evaluation program, and recording medium
AT9843U1 (de) 2007-03-27 2008-04-15 Kepplinger Berthold Dr Messung von biologischen markern
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
WO2009100243A2 (en) * 2008-02-05 2009-08-13 University Of Miami Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients
JPWO2011019072A1 (ja) 2009-08-12 2013-01-17 ヒューマン・メタボローム・テクノロジーズ株式会社 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596134B1 (de) 2010-07-23 2020-04-08 President and Fellows of Harvard College Verfahren zur erkennung von erkrankungen oder leiden mit phagozytischen zellen
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP4303584A3 (de) 2010-07-23 2024-04-03 President and Fellows of Harvard College Verfahren zur erkennung von anzeichen für krankheiten oder leiden in körperflüssigkeiten
WO2013069645A1 (ja) 2011-11-10 2013-05-16 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
AU2013273984A1 (en) 2012-06-15 2015-01-22 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
US20150275298A1 (en) 2012-06-15 2015-10-01 Harry Stylli Methods of detecting diseases or conditions
WO2014068144A1 (en) 2012-11-05 2014-05-08 Ospedale San Raffaele S.R.L. Biomarkers of multiple myeloma development and progression
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
EP2799878A1 (de) * 2013-05-03 2014-11-05 SALION GmbH In vitro Verfahren zur Früherkennung von potenziellen Entzündungen, insbesondere im Zusammenhang mit der Abstoßung eines Transplantats
US20160003857A1 (en) * 2014-07-02 2016-01-07 Cecil Bennett Methods and systems for detecting polypharmacy
EP4428251A3 (de) 2014-09-11 2024-12-18 Immunis.AI, Inc. Verfahren zum nachweis von prostatakrebs
US11806385B2 (en) 2016-04-22 2023-11-07 Board Of Regents Of The University Of Nebraska Biomarkers for monitoring immune transformation
EP3413050A1 (de) * 2017-06-08 2018-12-12 SALION GmbH In vitro verfahren zur erkennung neurodegenerativer erkrankungen
EP3688186A4 (de) * 2017-09-27 2021-10-13 University of North Carolina Wilmington Menschliches abwasser und vom menschen abgeleitetes pathogensuchwerkzeug
WO2019181830A1 (ja) 2018-03-19 2019-09-26 富士フイルム和光純薬株式会社 精神疾患の判定方法
CN111315420A (zh) * 2018-03-22 2020-06-19 株式会社日本医疗机器技研 生物可吸收支架
KR102159344B1 (ko) * 2019-08-05 2020-09-23 한국과학기술연구원 행위 중독의 진단용 조성물, 키트 및 이를 이용한 행위 중독의 진단을 위한 키누레닌의 검출 방법
WO2021106724A1 (ja) * 2019-11-26 2021-06-03 京セラ株式会社 ストレス計測システムおよびストレス計測方法
JP2023549028A (ja) * 2020-10-06 2023-11-22 学校法人沖縄科学技術大学院大学学園 アルツハイマー病（ａｄ）の診断のための指標を得るための方法
JPWO2024253194A1 (de) * 2023-06-08 2024-12-12
CN118566488B (zh) * 2024-04-10 2026-02-27 合肥歆智医疗器械有限公司 抑郁症检测用试剂组合、制造方法、检测系统及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194217B1 (en) * 1980-01-14 2001-02-27 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
JP2000131318A (ja) * 1998-10-22 2000-05-12 Nikken Foods Co Ltd 快・不快ストレス状態解析方法
EP1050758A1 (de) * 1999-05-03 2000-11-08 Evotec BioSystems AG Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Neurotrophin 3-Spiegel basiert sind
FR2827045B1 (fr) * 2001-07-05 2007-08-10 Univ Pasteur Methodes et compositions pour la selection et le developpement de nouveaux agents pharmacologiques ou de nouveaux medicaments
JP2004198325A (ja) * 2002-12-19 2004-07-15 Oriental Yeast Co Ltd ストレスの測定方法

Also Published As

Publication number Publication date
PL2146209T3 (pl) 2012-05-31
ES2377704T3 (es) 2012-03-30
ES2346467T3 (es) 2010-10-15
EP2146209A1 (de) 2010-01-20
PT2146209E (pt) 2011-12-30
SI1866650T1 (sl) 2010-12-31
WO2006105907A1 (en) 2006-10-12
US20120196300A1 (en) 2012-08-02
DE602006014379D1 (de) 2010-07-01
NO20075671L (no) 2007-11-06
ATE468537T1 (de) 2010-06-15
EP1866650A1 (de) 2007-12-19
HK1137219A1 (en) 2010-07-23
CY1110116T1 (el) 2015-01-14
US20080131921A1 (en) 2008-06-05
JP4958893B2 (ja) 2012-06-20
JP2008537111A (ja) 2008-09-11
PT1866650E (pt) 2010-06-01
DK2146209T3 (da) 2012-02-13
NO20120452L (no) 2007-11-06
EP1866650B1 (de) 2010-05-19
PL1866650T3 (pl) 2011-04-29
DK1866650T3 (da) 2010-09-06
EP2146209B1 (de) 2011-11-16

Similar Documents

Publication Publication Date Title
ATE534038T1 (de) Neurodegenerative marker für alzheimer-krankheit
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
CY1112737T1 (el) Ισοτοπικα σεσημασμενες ενωσεις βενζοfuran σαν παραγοντες απεικονισης για πρωτεϊνες δημιουργιας αμυλοειδους (αμυloid)
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
DK1719116T3 (da) Skift fra ACELP- til TCX-indkodningstilstand
EP1956962A4 (de) Verfahren zur bestimmung der form eines biegbaren instruments
EP1872705A4 (de) Endoskopförmige nachweisvorrichtung
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
EP2062052A4 (de) Verfahren zur bestimmung einer analytkonzentration
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
FR2874675B1 (fr) Frein pour roue avec capteur d'usure
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
EP1856526A4 (de) Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
EP1877154A4 (de) Verfahren zur detektion, identifizierung und quantifizierung von verunreinigungen
ATE530548T1 (de) Neue dibenzoäc,hüä1,5ü naphthyridine und ihre verwendung als dna-sonden
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
BRPI0512655A (pt) bioexame de rna
DE60324820D1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo
FR2852096B1 (fr) Instrument indicateur de direction permettant d'indiquer l'heure et la direction de la mecque.
ATE442084T1 (de) Messung des energieverbrauchs
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
WO2008148493A3 (en) Annexin a5 and annexin a6 as biomarkter for alzheimer's disease